Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EYE103 vs ranibizumab in diabetic macular edema
2025-520809-12-00Phase 3Authorised
- Sponsor
- EyeBio
- Start
- Jun 2025
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of restoret in diabetic macular edema (DME) (3 arms), sponsored by EyeBio. Primary endpoint: Change in ETDRS BCVA from baseline to Year 1. Planned start Jun 2025; status: authorised.
02
Drugs
restoret
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2025-520809-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520809-12-00.